INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA):IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Article

New Therapeutic approaches for Migraine: A brief overview

Dipali V. Mane*, Rashmi R. Balkate , Vanita H. Shinde

Assistant Professor, Shriram Shikshan Snatha's College of Pharmacy, Paniv-413113

ARTICLE INFO

Received: 10 Jan 2024
Accepted: 14 Jan 2024
Published: 24 Jan 2024
Keywords:
Migraine, Neurological disorder, Headache, Treatment options, Quality of life
DOI:
10.5281/zenodo.10557272

ABSTRACT

A common neurological condition called migraine is typified by recurrent, throbbing headaches that are frequently accompanied by other symptoms like nausea, light sensitivity, and aura. An extensive review of migraine, including its epidemiology, pathophysiology, clinical manifestation, triggers, and risk factors, is given in this work. There is a discussion of the diagnostic standards and the many acute and preventive treatment choices. The effects of migraines on one's physical and psychological well-being are examined, highlighting the necessity of managing the condition holistically. The article also explores recent findings and novel treatments, emphasizing how migraine treatment is developing. This succinct summary seeks to raise knowledge and comprehension of migraine, encouraging better management techniques and better results for those who suffer from this crippling ailment..

INTRODUCTION

A careful analysis of the description, categorization, and neurological disorder status of migraine, a complicated and incapacitating ailment, is necessary to have a comprehensive grasp of this condition. A migraine is more than just a really bad headache; it's a neurological condition marked by pulsating, repeated headaches that are frequently accompanied by other symptoms including light sensitivity, nausea, and, in rare cases, brain abnormalities called auras. Its episodic structure, with separate stages of onset, attack, & resolution, is what makes it unique1-3.

CLASSIFICATION:

There are two basic types of migraines: migraine without aura and migraine with aura. Reversible neurological symptoms such as tingling sensations or vision abnormalities precede or accompany the headache during the aura phase. Using this classification approach makes it easier to customize treatment plans based on the unique traits and symptoms of each migraine type4-5.

***Corresponding Author:** Dipali V. Mane
Address: *Assistant Professor, Shriram Shikshan Snatha's College of Pharmacy, Paniv-413113*
Email : dipsthaware1993@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



Figure No. 01: Basic types of migraines

The neurological disorder known as migraine

1. Neurological Basis:

The core cause of migraines is abnormalities in the central nervous system. Unbalances in neurotransmitters, especially those pertaining to serotonin, are important factors in the beginning and development of migraine attacks. A wave of neuronal depolarization known as cortical spreading depression contributes to the aura phase, highlighting the complex neurological processes involved6-9.

2. Genetic and Environmental Factors:

Studies point to a high hereditary component for migraines, identifying certain genes linked to pain pathways and neural excitability. The neuronal landscape of migraine is further complicated by the interaction of genetic variables and environmental triggers, such as stress, particular meals, or hormone changes10-13.

Distinguishing Migraines from Other Headache Types

1. Distinctive Characteristics

Cluster headaches and tension-type headaches are not the same as migraines due to their distinct presentation. These include the pulsing nature of the pain, its unilateral location, the aggravating effect of regular physical activity, and its correlation with light and sound sensitivity or nausea14-15.

2. Diagnostic Criteria:

Strict criteria for diagnosing migraines are provided by the International Classification of Headache Disorders (ICHD), guaranteeing a uniform procedure. These factors help medical professionals distinguish migraines from other headache illnesses by taking into account the length, frequency, and particular characteristics of headaches16-17.

EPIDEMIOLOGY

According to the International Headache Society (IHS), migraines account for 16% of primary headaches and affect 10–20% of the world's population. They are a common cause of recurrent headaches. Unbelievably, over two thirds of migraine sufferers either never see a doctor or stop seeing one after experiencing a migraine, which leads to an underdiagnosis and insufficient treatment for this ailment. As the World Health Organization (WHO) notes, migraine is one of the most incapacitating medical conditions globally, with severe repercussions that even worsen quality of life. Around the world, 10-15% of men and 15-20% of women suffer from migraines; in India, the prevalence is said to be between 15-20% of the general population. Notably, males and girls are equally prone to migraines throughout childhood until adolescence, at which point there is a shift in frequency, with females showing a higher incidence, translating into a 2:1 female-to-male ratio in adulthood. This emphasizes how important it is to pay closer attention to the migraine

problem18. According to the World Federation of Neurology, migraine is a hereditary condition marked by recurrent episodes of headaches that can differ greatly in terms of severity, frequency, and length. These episodes are frequently unilateral and are frequently followed by nausea, vomiting, and anorexia. A typical migraine headache lasts between four to seventy-two hours and is characterized by pulsing, unilateral discomfort that affects one half of the brain. Nausea, vomiting, photophobia (high sensitivity to light), phonophobia (high sensitivity to sound), and agitation from regular activities are among the associated symptoms. Auras, which are peculiar visual, olfactory, or other sensory experiences that indicate the start of a migraine attack, are also experienced by roughly one-third of migraineurs19-20. Migraine has a significant effect on people that goes beyond just physical discomfort. Because migraine attacks are erratic, they interfere with everyday tasks, reducing productivity and lowering general quality of life. Emotional anguish and a reduction in social functioning are frequently brought on by the continuous, throbbing pain and its accompanying symptoms. From a societal standpoint, migraines are a major source of financial problems. Significant financial losses arise from migraine episodes-related absenteeism and decreased productivity at work. The economic impact is further increased by the use of healthcare for migraine management, which emphasizes the need for efficient preventative and treatment measures21-22.

Gender and Age Distribution

There is a clear gender disparity in migraine, with a higher frequency in women. Hormonal changes, especially those associated with the menstrual cycle, frequently affect the incidence of migraines. The complicated interplay between genetic, hormonal, and environmental factors is responsible for the gender gap, and it goes beyond simple hormone differences. Although migraines can occur at any age, there are observable age-related trends. The appearance of childhood migraines is often different from that of adult migraines, and the frequency of these headaches peaks in the productive years of adulthood. The frequency and severity of migraine attacks may lessen with age, although age-related variables including hormonal shifts or co-occurring medical disorders may affect the occurrence of migraines in later life23-24.

Pathophysiology

A. Mechanisms of Neurology

The etiology of migraines is closely associated with the imbalance of neurotransmitters, namely serotonin. A series of events are set off by a drop in serotonin levels that occurs during the premonitory period. Vasoconstriction and ischemia result from a subsequent rise in serotonin as the crisis intensifies. Furthermore, additional neurotransmitters that affect vascular dilatation and neurogenic inflammation, such as calcitonin gene-related peptide (CGRP), are essential for the onset and maintenance of migraine discomfort25-27.

Vascular and Cortical Changes during a Migraine Attack

a. Vascular Changes:

The blood supply to the brain is dynamically altered during migraine attacks. Vasoconstriction is a feature of the early phase, which may be related to the aura symptoms. Vasodilation, especially in the meningeal blood vessels, occurs next, which causes the throbbing pain that is specific to migraines. Vasoactive chemicals, such as CGRP, are released, which aggravates vascular alterations and encourages vasodilation and neurogenic inflammation28-29.

b. Cortical Changes:

When a migraine aura occurs, a phenomenon known as cortical spreading depression (CSD) is seen. It causes a wave of

depolarization of neurons throughout the cerebral cortex, which results in momentary neurological symptoms. It is believed that this phenomenon has a role in the motor, sensory, or visual auras that migraineurs experience. The intricate neurological mechanisms underlying the pathophysiology of migraines are highlighted by the interaction between vascular and cortical alterations. Gaining knowledge of the subtleties of vascular dynamics, brain alterations, and neurotransmitter dysregulation during a migraine attack can help identify new treatment targets. More efficient migraine treatment and prevention may be possible with targeted therapies that alter this pathways30-32.

Migraine theories:

1. **The Depolarization Theory:**

The Depolarization Theory, which proposes a link between cortical spreading depression (CSD) and migraine aura, is one idea put out to explain the pathophysiology of migraines. This theory states that CSD is caused by the first activation and then depression of neural activity in a particular region of the cortex of the brain. It is hypothesized that this event triggers the production of inflammatory mediators that irritate cranial nerve roots, especially the trigeminal nerve, which is in charge of processing sensory data related to the face and head. Nevertheless, there is little data to support this notion because only a small percentage of migraineurs have auras, and those who do not show cortical spreading depression. Furthermore, the exclusivity of this notion is called into question by the existence of prodromes that occur days before to the aura6, 26, 33, 34



Figure No. 02: Migraine Theories

2. **Vascular Theory:**

According to this alternative viewpoint, migraines are caused by abnormal blood vessel contraction and expansion in the brain. Some people may get an aura as a result of the process starting with occipital lobe artery spasms. The veins widen too much when they dilate, which causes permeability and fluid leakage. When the body detects this leakage, pain receptors in the surrounding tissue trigger the release of inflammatory chemicals. The Vascular Theory was formerly thought to be primary, but it is now thought to be secondary to underlying brain dysfunction35.

3. **Serotonin Theory:**

This neurotransmitter regulates mood, pain perception, and blood vessel constriction. It is the subject of much research. Migraine may be brought on by low serotonin levels, which can cause a cycle of blood vessel dilatation and constriction. Triptans, LSD, and psilocin are examples of serotonin receptor-activating drugs known as serotonergic agonists that can stop a migraine attack36.

4. **Neural Theory:**

According to this theory, migraines start when particular nerves or regions of the brainstem

become irritated. In response, the body releases chemicals that irritate neurons and cause blood vessel inflammation, which results in pain. By sending pain signals to the brain, substance P, which is released during the initial irritation, increases pain37.

5. Unifying Theory:

According to this comprehensive perspective, migraines are caused by both vascular and neurological mechanisms. Stress causes alterations in the brain that result in the release of serotonin and the constriction and dilation of blood vessels. A more comprehensive understanding of the pathophysiology of migraines is possible because of this intricate interaction and the production of chemicals like substance P, which cause neurogenic inflammation and pain38-39.

Triggers and Risk Factors

Dietary Triggers40-42:

1. Tyramine and Histamine:

Some foods have been linked to migraines, including those high in histamine (like red wine) and tyramine (like old cheese). In those who are vulnerable, these chemicals may cause vasoconstriction and the release of inflammatory mediators, which may exacerbate headaches.

2. Caffeine and Withdrawal:

Migraines can be brought on by abrupt withdrawal from caffeine as well as excessive intake. While moderation in caffeine use may help, stopping suddenly can cause vasodilation and headaches.

3. Food Additives:

In certain people, certain additives—like artificial sweeteners and monosodium glutamate (MSG)—have been linked to migraines. Because people's sensitivity to these chemicals varies, they could act as triggers for those who are sensitive.

Stress and Sleep Habits43-47:

1. Stress:

It is generally known that long-term stress can cause migraines. Stressful circumstances can cause the release of hormones and neurotransmitters that alter blood vessels and make people more prone to migraines. Relaxation exercises and other stress-reduction strategies could lessen the impact of this trigger.

2. Irregular Sleep Schedules:

Variations in sleep schedules, such as getting too little sleep or too much sleep, can cause headaches. The equilibrium of the nervous system depends on sleep, and sleep disruptions can affect neurotransmitter levels, which increases the risk of migraines.

3. Sleep Disorders:

There is a link between a higher risk of migraines and conditions like sleep apnea or insomnia. For those who suffer from migraines, addressing and treating sleep disturbances might be crucial to migraine management. A key component of managing migraines is identifying and resolving environmental and lifestyle causes, such as stress, food, and sleep habits. A comprehensive strategy to lessen the frequency and intensity of migraine attacks includes tailored tactics that recognize and address these triggers48-49.

Diagnosis

Criteria for Diagnosing Migraines

Guidelines from International Headache Societies50-51:

1. International Classification of Headache Disorders (ICHD):

Developed by global headache associations, the ICHD offers defined diagnostic standards for a range of headache conditions, including migraines. It outlines the precise features, length, and frequency of headache episodes together with related symptoms, making it possible for medical practitioners to precisely classify and diagnose migraines.

2. Updates and Revisions:

Periodic revisions to diagnostic criteria are prompted by ongoing research and clinical breakthroughs. International headache societies update its guidelines to take into account new

research and make sure that the diagnostic standards continue to reflect the state of knowledge regarding the pathophysiology of migraines.

Importance of Patient History and Symptom Tracking52-54:

1. **Detailed Patient History:**

The diagnostic process depends on having a complete patient history. Medical experts ask about the type, duration, and frequency of headaches in addition to related symptoms including light or sound sensitivity, nausea, and aura. Accurate diagnosis is aided by knowledge about the patient's medical history, family history, and possible triggers.

2. Symptom Tracking:

Using smartphone applications or encouraging patients to keep a headache journal can help improve the accuracy of diagnosis. It is helpful to document the beginning, length, and severity of headaches as well as any possible triggers and concomitant symptoms. Tracking patterns help with diagnosis confirmation and treatment plan customization.

3. **Differential Diagnosis:**

It is important to distinguish migraines from other types of headaches due to the variety of headache diseases. In order to ensure effective and focused therapies, it is helpful to rule out secondary causes and establish a definitive diagnosis with the use of the patient's history and symptom tracking.

A thorough patient history, methodical symptom tracking, and an accurate diagnosis informed by internationally recognized criteria serve as the cornerstones of successful migraine treatment. With this all-encompassing approach, medical practitioners may better meet the specific needs of each patient and improve the general standard of treatment for migraineurs.

Treatment:

Acute Treatment

Medications for Symptom Relief55-57:

1. **Painkillers:**

For mild to moderate migraines, common over-the-counter painkillers like acetaminophen or nonsteroidal anti-inflammatory medications (NSAIDs), like ibuprofen, can be used.

2. **Triptans:**

Prescription drugs that especially address the symptoms of migraines are known as triptans. They function by narrowing blood arteries and obstructing the brain's pain pathways. There are several formulations and administration systems available to suit different migraineurs' preferences and features.

3. **Anti-Nausea Drugs:**

In order to enhance overall symptom management, medications that address nausea and vomiting—two typical symptoms of migraines—may be used in addition to other treatments.

Lifestyle Interventions during an Attack48:

1. **Rest and Relaxation:**

During a migraine episode, finding a quiet, dark area to rest in can help reduce sensory disturbances and promote calm.

2. **Nutrition and Hydration:**

Eating small, easily digested meals and staying hydrated can help manage symptoms and offset any fasting or dehydration triggers.

3. **Cold or Warm Compress:**

For some people, applying a cold or warm compress to the head or neck may be helpful. Patients can determine which choice best suits them by trying out both of them.

Strategies for Prevention49-65

Medications for Long-Term Management:

1. **Tricyclic antidepressants and beta-blockers:**

Due to their ability to prevent migraines, certain drugs, including beta-blockers and antidepressants, may be recommended. They support the control of neurotransmitter levels and blood vessel constriction.

2. **Anti-CGRP Monoclonal Antibodies:**

Recently, new drugs that specifically target the calcitonin gene-related peptide (CGRP) have been developed, providing a focused method of migraine prevention. Periodically delivered, these monoclonal antibodies have demonstrated effectiveness in decreasing the frequency and intensity of migraine attacks.

Changes in Behaviour and Lifestyle:

1. **Stress management:**

Since stress is a typical migraine trigger, people can benefit from practices like biofeedback, mindfulness meditation, and relaxation exercises.

2. **Regular Exercise:**

Physical activity on a regular basis improves general health and may lessen migraine frequency. But people have to be careful not to overdo it when they're under attack.

3. **Sleep hygiene:**

Creating a sleep-friendly environment and establishing regular sleep schedules help avoid migraines. If sleep disturbances exist, treating them is essential to long-term care. A comprehensive approach to migraine management combines preventive measures with acute therapeutic alternatives. More efficient and individualized treatment for migraineurs can be achieved by addressing lifestyle factors and customizing interventions to meet specific needs66.

Current Research and Advancements

A. Emerging Therapies67-71

New Drugs:

1. **CGRP Receptor Antagonists:**

Continued research has resulted in the creation of drugs that particularly target the calcitonin gene-related peptide (CGRP) pathway. These antagonists of the CGRP receptor seek to prevent the effects of CGRP, which is thought to be involved in the start and progression of migraines.

2. **Gepants:**

A novel family of drugs called gepants is intended to specifically inhibit the calcitonin gene-related peptide (CGRP) receptor's function. Since gepants do not constrict blood vessels like triptans do, they may be a viable alternative for people who should not use triptans.

3. **5-HT1F Receptor Agonists:**

Research on serotonin receptors has produced 5-HT1F receptor agonists, which provide a fresh method of treating migraines. By focusing on serotonin receptors in the trigeminal nerve system, these drugs alter how pain is transmitted.

Technological Approaches72-79:

1. **Neuromodulation Devices:**

The usefulness of novel neuromodulation devices in the treatment of migraines is being studied. The goal of devices like non-invasive vagus nerve stimulators and transcranial magnetic stimulators is to change neural activity in order to lessen the frequency and intensity of migraine attacks.

2. **Smartphone Applications for Monitoring and Intervention:**

As mobile health technology has developed, so too have applications for monitoring and treating migraines. These applications frequently offer tools for monitoring symptoms, locating triggers, and providing tailored responses, all of which support more proactive and customized treatment.

3. **Virtual Reality (VR) Therapy:**

As a non-pharmacological migraine treatment, virtual reality therapy is being investigated in preliminary studies. Virtual reality (VR) environments are intended to help people relax and divert their attention from their discomfort, potentially serving as an adjunct to conventional treatments. Promising findings are being produced by ongoing research on the management of migraines, with an emphasis on specialized drugs and technology advancements. These cutting-edge treatments mark a significant leap forward in migraine therapy, providing fresh opportunities for more individualized and successful regimens80-81.

CONCLUSION

To sum up, migraines are known to be complex neurological conditions that have a significant impact on global health and exhibit unique patterns related to age and gender. Vascular alterations, cortical spreading depression, and neurotransmitter dysregulation are a few of the intricate neurological processes involved in the pathogenesis. The international headache society's criteria, thorough patient histories, and symptom recording are essential for accurate diagnosis. Because migraines are complex conditions, treating them requires a multidisciplinary team that includes psychologists, neurologists, pain specialists, and other medical specialists. Treatment methods include lifestyle adjustments and medication for acute relief; preventative measures and behavioral alterations are used for long-term maintenance. Research on new drugs and technology interventions is ongoing, reflecting the ever-changing field of developing therapeutics. In order to provide individualized care, it is critical to acknowledge the significance of environmental triggers and risk factors, such as dietary impacts and stress. In the end, a holistic approach to understanding and treating migraines highlights the importance of teamwork in order to ensure thorough and customized therapies that take into account the various facets of this neurological condition and enhance the general quality of life for individuals who are impacted.

REFERENCES

1. Gupta J, Gaurkar S S (August 24, 2022) Migraine: An Underestimated Neurological Condition Affecting Billions. Cureus 14(8): e28347. doi:10.7759/cureus.28347
2. Weatherall MW. The diagnosis and treatment of chronic migraine. Therapeutic Advances in Chronic Disease. 2015;6(3):115-123. doi:10.1177/2040622315579627
3. Stovner, L.J., Hagen, K., Linde, M. et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23, 34 (2022). https://doi.org/10.1186/s10194-022-01402-2
4. Johra Khan, Et. al,Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine,Biomedicine&Pharmacotherapy,Volume 139,2021,111557,ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2021.111557.
5. PescadorRuschel MA, De Jesus O. Migraine Headache. [Updated 2023 Aug 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560787/
6. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 Apr;97(2):553-622. doi: 10.1152/physrev.00034.2015. PMID: 28179394; PMCID: PMC5539409.
7. Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012 Apr;19(2):88-94. doi: 10.5214/ans.0972.7531.12190210. PMID: 25205974; PMCID: PMC4117050.
8. Simonetta I, Riolo R, Todaro F, Tuttolomondo A. New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach. International Journal of Molecular Sciences. 2022; 23(6):3018. https://doi.org/10.3390/ijms23063018
9. Spekker E, Nagy-Grócz G, Vécsei L. Ion Channel Disturbances in Migraine Headache: Exploring the Potential Role of the Kynurenine System in the Context of the Trigeminovascular System. International Journal of Molecular Sciences. 2023;

24(23):16574. https://doi.org/10.3390/ijms242316574

10. Bron C, Sutherland HG, Griffiths LR. Exploring the Hereditary Nature of Migraine. Neuropsychiatr Dis Treat. 2021 Apr 22;17:1183-1194. doi: 10.2147/NDT.S282562. PMID: 33911866; PMCID: PMC8075356.
11. Fila M, Pawłowska E, Blasiak J. Mitochondria in migraine pathophysiology - does epigenetics play a role? Arch Med Sci. 2019 Jul;15(4):944-956. doi: 10.5114/aoms.2019.86061. Epub 2019 Jun 20. PMID: 31360189; PMCID: PMC6657237.
12. Pleș H, Florian I-A, Timis T-L, Covache-Busuioc R-A, Glavan L-A, Dumitrascu D-I, Popa AA, Bordeianu A, Ciurea AV. Migraine: Advances in the Pathogenesis and Treatment. Neurology International. 2023; 15(3):1052-1105. https://doi.org/10.3390/neurolint15030067
13. Soumitra Ghosh and Warren G. Tourtellotte, The Complex Clinical and Genetic Landscape of Hereditary Peripheral Neuropathy, Annual Review of Pathology: Mechanisms of Disease 2021 16:1, 487-509, https://doi.org/10.1146/annurev-pathol-030320-100822
14. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012 Aug;6(3):124-32. doi: 10.1177/2049463712459691. PMID: 26516483; PMCID: PMC4590146.
15. Ravishankar K. The art of history-taking in a headache patient. Ann Indian Acad Neurol. 2012 Aug;15(Suppl 1):S7-S14. doi: 10.4103/0972-2327.99989. PMID: 23024567; PMCID: PMC3444228.
16. Weatherall MW. The diagnosis and treatment of chronic migraine. TherAdv Chronic Dis. 2015 May;6(3):115-23. doi: 10.1177/2040622315579627. PMID: 25954496; PMCID: PMC4416971.
17. Eigenbrodt AK, et. al, Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514. doi: 10.1038/s41582-021-00509-5. Epub 2021 Jun 18. PMID: 34145431; PMCID: PMC8321897.
18. Bahra A. Primary Headache Disorders: Focus on Migraine. Rev Pain. 2011 Dec;5(4):2-11. doi: 10.1177/204946371100500402. PMID: 26525886; PMCID: PMC4590049.
19. Amiri P, et al Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605. PMID: 35281991; PMCID: PMC8904749.
20. Bron C, et al Exploring the Hereditary Nature of Migraine. Neuropsychiatr Dis Treat. 2021 Apr 22;17:1183-1194. doi: 10.2147/NDT.S282562. PMID: 33911866; PMCID: PMC8075356.
21. Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009 May;84(5):422-35. doi: 10.1016/S0025-6196(11)60561-2. PMID: 19411439; PMCID: PMC2676125.
22. Burton WN, Landy SH, Downs KE, Runken MC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009 May;84(5):436-45. doi: 10.1016/S0025-6196(11)60562-4. PMID: 19411440; PMCID: PMC2676126.
23. Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann JL. Giving Researchers a Headache - Sex and

Gender Differences in Migraine. Front Neurol. 2020;11:549038. Published 2020 Oct 22. doi:10.3389/fneur.2020.549038

24. Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C. Gender-related differences in migraine. Neurol Sci. 2020;41(Suppl 2):429-436. doi:10.1007/s10072-020-04643-8
25. Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012;19(2):88-94. doi:10.5214/ans.0972.7531.12190210
26. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622. doi:10.1152/physrev.00034.2015
27. Panconesi, A. Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 9, 267–276 (2008). https://doi.org/10.1007/s10194-008-0058-2
28. Charles A, Brennan KC. The neurobiology of migraine. Handb Clin Neurol. 2010;97:99-108. doi:10.1016/S0072-9752(10)97007-3
29. Mason BN and Russo AF (2018) Vascular Contributions to Migraine: Time to Revisit? Front. Cell. Neurosci. 12:233. doi: 10.3389/fncel.2018.00233
30. Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab. 2011;31(1):17-35. doi:10.1038/jcbfm.2010.191
31. Cui Y, Kataoka Y, Watanabe Y. Role of cortical spreading depression in the pathophysiology of migraine. Neurosci Bull. 2014;30(5):812-822. doi:10.1007/s12264-014-1471-y
32. Harriott, A.M., Takizawa, T., Chung, D.Y. et al. Spreading depression as a preclinical model of migraine. J Headache Pain 20, 45 (2019). https://doi.org/10.1186/s10194-019-1001-4
33. Costa, C., Tozzi, A., Rainero, I. et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain 14, 62 (2013). https://doi.org/10.1186/1129-2377-14-62
34. Rogawski MA. Common Pathophysiologic Mechanisms in Migraine and Epilepsy. Arch Neurol. 2008;65(6):709–714. doi:10.1001/archneur.65.6.709
35. Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol. 2010;9(3):309-317. doi:10.1016/S1474-4422(09)70358-8
36. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366. doi:10.1146/annurev.med.60.042307.110802
37. Malhotra R. Understanding migraine: Potential role of neurogenic inflammation. Ann Indian Acad Neurol. 2016;19(2):175-182. doi:10.4103/0972-2327.182302
38. Shibata Y. Migraine Pathophysiology Revisited: Proposal of a New Molecular Theory of Migraine Pathophysiology and Headache Diagnostic Criteria. International Journal of Molecular Sciences. 2022; 23(21):13002. https://doi.org/10.3390/ijms232113002
39. Pleș H, Florian I-A, Timis T-L, Covache-Busuioc R-A, Glavan L-A, Dumitrascu D-I, Popa AA, Bordeianu A, Ciurea AV. Migraine: Advances in the Pathogenesis and Treatment. Neurology International. 2023; 15(3):1052-1105. https://doi.org/10.3390/neurolint15030067

40. Papetti L, Moavero R, Ferilli MAN, et al. Truths and Myths in Pediatric Migraine and Nutrition. Nutrients. 2021;13(8):2714. Published 2021 Aug 6. doi:10.3390/nu13082714
41. Gammone MA, Vicentini A, Riccioni G, De Girolamo M, D'Aulerio A, D'Orazio N. Food-Related Atrial Fibrillation? The Potential Role of Biogenic Amines in "Nutri-Arrhythmias" Genesis. Reports. 2019; 2(1):1. https://doi.org/10.3390/reports2010001
42. Finocchi, Cinzia & Sivori, Giorgia. (2012). Food as trigger and aggravating factor of migraine. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 33 Suppl 1. S77-80. 10.1007/s10072-012-1046-5.
43. Maleki N, Becerra L, Borsook D. Migraine: maladaptive brain responses to stress. Headache. 2012;52 Suppl 2(Suppl 2):102-106. doi:10.1111/j.1526-4610.2012.02241.x
44. Kang JH, Chen SC. Effects of an irregular bedtime schedule on sleep quality, daytime sleepiness, and fatigue among university students in Taiwan. BMC Public Health. 2009;9:248. Published 2009 Jul 19. doi:10.1186/1471-2458-9-248
45. Institute of Medicine (US) Committee on Sleep Medicine and Research; Colten HR, Altevogt BM, editors. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington (DC): National Academies Press (US); 2006. 3, Extent and Health Consequences of Chronic Sleep Loss and Sleep Disorders. Available from: https://www.ncbi.nlm.nih.gov/books/NBK19961/
46. Pergolizzi, J.V., Magnusson, P., LeQuang, J.A. et al. Exploring the Connection Between Sleep and Cluster Headache: A Narrative Review. Pain Ther 9, 359–371 (2020). https://doi.org/10.1007/s40122-020-00172-6
47. Luciana Besedovsky, Tanja Lange, and Monika Haack, The Sleep-Immune Crosstalk in Health and Disease, Physiological Reviews 2019 99:3, 1325-1380
48. Agbetou M, Adoukonou T. Lifestyle Modifications for Migraine Management. Front Neurol. 2022;13:719467. Published 2022 Mar 18. doi:10.3389/fneur.2022.719467
49. D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat. 2008;4(6):1155-1167. doi:10.2147/ndt.s3497
50. Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6(3):115-123. doi:10.1177/2040622315579627
51. Eigenbrodt, A.K., Ashina, H., Khan, S. et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17, 501–514 (2021). https://doi.org/10.1038/s41582-021-00509-5
52. Ravishankar K. The art of history-taking in a headache patient. Ann Indian Acad Neurol. 2012;15(Suppl 1):S7-S14. doi:10.4103/0972-2327.99989
53. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012;6(3):124-132. doi:10.1177/2049463712459691
54. Steiner, T.J., Jensen, R., Katsarava, Z. et al. Aids to management of headache disorders in primary care (2nd edition). J Headache Pain 20, 57 (2019). https://doi.org/10.1186/s10194-018-0899-2
55. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel). 2010;3(6):1966-1987. Published 2010 Jun 17. doi:10.3390/ph3061966
56. Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their

Potential Mechanisms of Action [published correction appears in Neurotherapeutics. 2018 Jan 8;:]. Neurotherapeutics. 2018;15(2):274-290. doi:10.1007/s13311-017-0592-1

57. Laura Mayans, Acute Migraine Headache: Treatment Strategies, Am Fam Physician. 2018;97(4):243-251
58. Kumar A, Kadian R. Migraine Prophylaxis. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507873/
59. Silberstein, Stephen, "Preventive treatment of migraine" (2006).Department of Neurology, Faculty Papers. Paper 19., https://jdc.jefferson.edu/neurologyfp/19
60. Silberstein SD. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973-989. doi:10.1212/CON.0000000000000199
61. Duncan Smyth, Zelie Britton, Louisa Murdin, Qadeer Arshad, Diego Kaski, Vestibular migraine treatment: a comprehensive practical review, Brain, Volume 145, Issue 11, November 2022, Pages 3741–3754, https://doi.org/10.1093/brain/awac264
62. Pallapothu M R, Quintana Mariñez M G, Chakkera M, et al. (October 08, 2023) Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP). Cureus 15(10): e46696. doi:10.7759/cureus.46696
63. Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clinical and Translational Neuroscience. 2019;3(1). doi:10.1177/2514183X18823377
64. Simonetta I, Riolo R, Todaro F, Tuttolomondo A. New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach. International Journal of Molecular Sciences. 2022; 23(6):3018. https://doi.org/10.3390/ijms23063018
65. Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201. PMID: 30725283.
66. Haghdoost F, Togha M. Migraine management: Non-pharmacological points for patients and health care professionals. Open Med (Wars). 2022;17(1):1869-1882. Published 2022 Nov 23. doi:10.1515/med-2022-0598
67. Rashid A, Manghi A. Calcitonin Gene-Related Peptide Receptor. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560648/
68. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099-1142. doi:10.1152/physrev.00034.2013
69. Deen, M., Correnti, E., Kamm, K. et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain 18, 96 (2017). https://doi.org/10.1186/s10194-017-0807-1
70. Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, Tonin P and Corasaniti MT (2019) New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies. Front. Pharmacol. 10:363. doi: 10.3389/fphar.2019.00363

71. Garelja, M. L., Walker, C. S., & Hay, D. L. (2022). CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists? British Journal of Pharmacology, 179(3), 454–459. https://doi.org/10.1111/bph.15585
72. Rashid A, Manghi A. Calcitonin Gene-Related Peptide Receptor. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560648/
73. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099-1142. doi:10.1152/physrev.00034.2013
74. Deen, M., Correnti, E., Kamm, K. et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain 18, 96 (2017). https://doi.org/10.1186/s10194-017-0807-1
75. Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, Tonin P and Corasaniti MT (2019) New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies. Front. Pharmacol. 10:363. doi: 10.3389/fphar.2019.00363
76. Garelja, M. L., Walker, C. S., & Hay, D. L. (2022). CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists? British Journal of Pharmacology, 179(3), 454–459. https://doi.org/10.1111/bph.15585
77. Miller S, Sinclair AJ, Davies B, et al Neurostimulation in the treatment of primary headaches, Practical Neurology 2016;16:362-375.
78. Todd J. Schwedt, Bert Vargas, Neurostimulation for Treatment of Migraine and Cluster Headache, Pain Medicine, Volume 16, Issue 9, September 2015, Pages 1827–1834, https://doi.org/10.1111/pme.12792
79. Coppola, G., Magis, D., Casillo, F. et al. Neuromodulation for Chronic Daily Headache. Curr Pain Headache Rep 26, 267–278 (2022). https://doi.org/10.1007/s11916-022-01025-x
80. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637. Published 2016 May 17. doi:10.1186/s40064-016-2211-8
81. Al-Quliti KW, Assaedi ES. New advances in prevention of migraine. Review of current practice and recent advances. Neurosciences (Riyadh). 2016;21(3):207-214. doi:10.17712/nsj.2016.3.20150506

HOW TO CITE: Dipali V. Mane, Rashmi R. Balkate , Vanita H. Shinde, New Therapeutic approaches for Migraine: A brief overview, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 1, 541-553. https://doi.org/10.5281/zenodo.10557272